1887

Journal of General Virology

Volume 95, Issue 9

Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin Free

Abstract

Low-level hepatitis C virus (HCV) RNA may persist in PBMCs after successful treatment of chronic hepatitis C, but the consequences of this phenomenon are unclear. Forty-nine patients who achieved a sustained virological response (SVR) after pegylated IFN and ribavirin therapy were analysed 52–66 months after the SVR. HCV RNA was detected in PBMCs from 18 patients (47.4 %), and PBMCs in two patients stained positive for non-structural protein 3 (NS3). Quantification of various cytokine and chemokine transcripts in PBMCs revealed that levels of IL-6, IL-8, IL-12, TNF-α and macrophage inflammatory protein 1β were significantly higher in HCV-positive patients than in HCV-negative individuals. In conclusion, persistence of HCV RNA in PBMCs of patients with a SVR appears to be associated with immune activation.

  • Received:
  • Accepted:
  • Published Online:
© 2014 The Authors
Erratum
This article contains a correction applying to the following content:
Corrigendum: Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.064709-0
2014-09-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/9/2004.html?itemId=/content/journal/jgv/10.1099/vir.0.064709-0&mimeType=html&fmt=ahah

References

  1. Akdis M. , Burgler S. , Crameri R. , Eiwegger T. , Fujita H. , Gomez E. , Klunker S. , Meyer N. , O’Mahony L. . & other authors ( 2011; ). Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. . J Allergy Clin Immunol 127:, 701––721. [CrossRef] [PubMed]
    [Google Scholar]
  2. Benjamini Y. , Hochberg Y. . ( 1995; ). Controlling the false discovery rate: a practical and powerful approach to multiple testing. . J R Stat Soc 57:, 289––300.
     [Google Scholar]
  3. Fujiwara K. , Allison R. D. , Wang R. Y. , Bare P. , Matsuura K. , Schechterly C. , Murthy K. , Marincola F. M. , Alter H. J. . ( 2013; ). Investigation of residual hepatitis C virus in presumed recovered subjects. . Hepatology 57:, 483––491. [CrossRef] [PubMed]
    [Google Scholar]
  4. Ghany M. G. , Nelson D. R. , Strader D. B. , Thomas D. L. , Seeff L. B. . American Association for Study of Liver Diseases ( 2011; ). An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. . Hepatology 54:, 1433––1444. [CrossRef] [PubMed]
    [Google Scholar]
  5. Haller O. , Frese M. , Kochs G. . ( 1998; ). Mx proteins: mediators of innate resistance to RNA viruses. . Rev Sci Tech 17:, 220––230.[PubMed]
    [Google Scholar]
  6. Jacobson I. M. , Cacoub P. , Dal Maso L. , Harrison S. A. , Younossi Z. M. . ( 2010; ). Manifestations of chronic hepatitis C virus infection beyond the liver. . Clin Gastroenterol Hepatol 8:, 1017––1029. [CrossRef] [PubMed]
    [Google Scholar]
  7. Jimenez-Sousa M. A. , Almansa R. , de la Fuente C. , Caro-Paton A. , Ruiz L. , Sanchez-Antolín G. , Gonzalez J. M. , Aller R. , Alcaide N. . & other authors ( 2010; ). Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. . Eur Cytokine Netw 21:, 84––91.[PubMed]
    [Google Scholar]
  8. Kisiel E. , Radkowski M. , Pawelczyk A. , Horban A. , Stanczak J. , Bukowska-Ośko I. , Caraballo Cortes K. , Kaźmierczak J. , Popiel M. , Laskus T. . ( 2014; ). Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders. . J Viral Hepat 21:, 424––429. [CrossRef] [PubMed]
    [Google Scholar]
  9. Laskus T. , Radkowski M. , Wang L. F. , Nowicki M. , Rakela J. . ( 2000; ). Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. . J Virol 74:, 1014––1017. [CrossRef] [PubMed]
    [Google Scholar]
  10. Livak K. J. , Schmittgen T. D. . ( 2001; ). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. . Methods 25, 402––408.[CrossRef]
    [Google Scholar]
  11. Machida K. , Cheng K. T. , Sung V. M. , Levine A. M. , Foung S. , Lai M. M. . ( 2006; ). Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. . J Virol 80:, 866––874. [CrossRef] [PubMed]
    [Google Scholar]
  12. Moser B. , Loetscher P. . ( 2001; ). Lymphocyte traffic control by chemokines. . Nat Immunol 2:, 123––128. [CrossRef] [PubMed]
    [Google Scholar]
  13. Pearlman B. L. , Traub N. . ( 2011; ). Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. . Clin Infect Dis 52:, 889––900. [CrossRef] [PubMed]
    [Google Scholar]
  14. Pham T. N. , MacParland S. A. , Mulrooney P. M. , Cooksley H. , Naoumov N. V. , Michalak T. I. . ( 2004; ). Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. . J Virol 78:, 5867––5874. [CrossRef] [PubMed]
    [Google Scholar]
  15. Pham T. N. , Mercer S. E. , Michalak T. I. . ( 2009; ). Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. . J Viral Hepat 16:, 547––556. [CrossRef] [PubMed]
    [Google Scholar]
  16. Quiroga J. A. , Martín J. , Navas S. , Carreño V. . ( 1998; ). Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. . J Infect Dis 178:, 247––251. [CrossRef] [PubMed]
    [Google Scholar]
  17. Radkowski M. , Gallegos-Orozco J. F. , Jablonska J. , Colby T. V. , Walewska-Zielecka B. , Kubicka J. , Wilkinson J. , Adair D. , Rakela J. , Laskus T. . ( 2005; ). Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. . Hepatology 41, 106––114.[CrossRef]
    [Google Scholar]
  18. Saleh M. G. , Tibbs C. J. , Koskinas J. , Pereira L. M. , Bomford A. B. , Portmann B. C. , McFarlane I. G. , Williams R. . ( 1994; ). Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. . Hepatology 20:, 1399––1404. [CrossRef] [PubMed]
    [Google Scholar]
  19. Viganò S. , Perreau M. , Pantaleo G. , Harari A. . ( 2012; ). Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. . Clin Dev Immunol 2012:, 485781. [CrossRef] [PubMed]
    [Google Scholar]
  20. Wilkinson J. , Radkowski M. , Eschbacher J. M. , Laskus T. . ( 2010; ). Activation of brain macrophages/microglia cells in hepatitis C infection. . Gut 59:, 1394––1400. [CrossRef] [PubMed]
    [Google Scholar]
  21. Zignego A. L. , Giannini C. , Gragnani L. . ( 2012; ). HCV and lymphoproliferation. . Clin Dev Immunol 2012:, 980942. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.064709-0
Loading
Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin
J. Gen. Virol. 95, 2004 (2014); https://doi.org/10.1099/vir.0.064709-0
/content/journal/jgv/10.1099/vir.0.064709-0
/content/journal/jgv/10.1099/vir.0.064709-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error